<DOC>
	<DOCNO>NCT02251691</DOCNO>
	<brief_summary>The main objective study compare drug compliance patient renal transplantation twice-daily tacrolimus-based immunosuppressive regimen . The rationale study access influence once-daily prolonged-release tacrolimus versus standard twice-daily tacrolimus drug compliance renal transplantation recipient base assumption once-daily dose regimen may help improve drug compliance .</brief_summary>
	<brief_title>Influence Once-daily Versus Twice-daily Immunosuppressant Renal Transplant</brief_title>
	<detailed_description>This study prospective , two-arm randomize open-label , phase IV study compare drug compliance patient prolonged-release once-daily tacrolimus versus standard twice-daily tacrolimus base regimen de novo renal transplantation . The investigator evaluate drug compliance patient twice-daily tacrolimus-based regimen use medication scale BAAISÂ® ( basal assessment adherence immunosuppressive medication scale )</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male female adult patient receive renal transplantation may enter study . The intention enroll 90 patient fulfil inclusion/exclusion criterion study . Sixty patient receive prolongedrelease oncedaily tacrolimus base therapy ; thirty patient receive standard twicedaily tacrolimus base therapy . Inclusion criterion Male female patient 2065 year age undergoing renal transplantation Patients informed potential risk side effect study Female patient childbearing potential must agree maintain effective birth control study . Patients fully inform give write informed consent participate study Exclusion criterion Donor age great 65 year Patients receive perfectly match kidney ( 6 match HLAA , B , DR ) Patients recipients multiple solid organ transplant Patients undergoing second subsequent transplantation Patients pretransplant PRA &gt; 20 % Patients ABO incompatibility positive lymphocytotoxicity Patients severe , active infection Patients abnormal liver profile ALT , AST , alkaline phosphatase total bilirubin &gt; 3 time upper normal limit Patient HIVpositive hepatitis C ( PCR+ ) B surface antigen positive Patients treat investigational drug therapy within one month prior entry treat within 6 month transplantation Patients history malignancy within last five year except excise squamous basal cell carcinoma Patients history alcohol drug abuse sign alcoholinduced organ damage , mental dysfunction factor limit ability comply fully study requirement . Patients require ongoing dose systemic immunosuppressive drug prior transplantation . Pregnant woman breastfeed mother period study . Patients allergy tacrolimus , macrolide antibiotic , steroid mycophenolate mofetil .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Compliance</keyword>
</DOC>